Document Detail


Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues.
MedLine Citation:
PMID:  17961169     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Bypassing therapy is usually necessary to control or prevent bleeding episodes in patients with haemophilia A or B and high-titre inhibitors. Factor VIII inhibitor bypassing activity (FEIBA) has a long history of successful use in the acute, surgical and prophylactic treatment settings, but safety concerns have made some reluctant to administer this bypassing agent. A review of the literature and clinical trial data show that FEIBA has a low prevalence of thrombosis, a low prevalence of anamnesis that does not impact haemostatic efficacy and an excellent record of pathogen safety and clinical tolerability.
Authors:
L M Aledort
Related Documents :
11995469 - Clinical application of argon plasma coagulation in endoscopic hemostasis for non-ulcer...
6343729 - Effect of positive end-expiratory pressure on excessive mediastinal bleeding after card...
2237719 - Preventing postoperative acute bleeding of the upper part of the gastrointestinal tract.
8440429 - Design of a microwave system for endoscopy: an experimental study of energy, tissue con...
3928509 - The combined local/systemic use of antifibrinolytics in hemophiliacs undergoing dental ...
17877729 - Safety and efficacy of a plasma-derived monoclonal purified factor viii concentrate dur...
21149399 - Novel silicone stent to treat tracheobronchial lesions: results of 35 patients.
18007259 - Thoracolumbar deformity arthrodesis stopping at l5: fate of the l5-s1 disc, minimum 5-y...
24398339 - Analysis of phase 3 telavancin nosocomial pneumonia data excluding patients with severe...
Publication Detail:
Type:  Journal Article; Review     Date:  2007-10-22
Journal Detail:
Title:  Haemophilia : the official journal of the World Federation of Hemophilia     Volume:  14     ISSN:  1365-2516     ISO Abbreviation:  Haemophilia     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2008-01-10     Completed Date:  2008-04-07     Revised Date:  2009-10-21    
Medline Journal Info:
Nlm Unique ID:  9442916     Medline TA:  Haemophilia     Country:  England    
Other Details:
Languages:  eng     Pagination:  39-43     Citation Subset:  IM    
Affiliation:
Mount Sinai School of Medicine, New York, NY 10029, USA. Louis.Aledort@mountsinai.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies
Blood Coagulation Factors / adverse effects,  therapeutic use*
Hemophilia A / complications,  drug therapy*,  immunology
Hemorrhage / prevention & control
Humans
Thrombosis / chemically induced
Chemical
Reg. No./Substance:
0/Antibodies; 0/Blood Coagulation Factors; 78690-39-8/Feiba

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Review of quality of life: menorrhagia in women with or without inherited bleeding disorders.
Next Document:  Kwoniella mangroviensis gen. nov., sp.nov. (Tremellales, Basidiomycota), a teleomorphic yeast from m...